An expert discusses the rapidly evolving landscape of ITP treatments, highlighting emerging therapies such as Bruton’s tyrosine kinase inhibitors, neonatal Fc receptor antagonists, anti-CD38 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results